popup

Chen, 2022

cilgavimab and tixagevimab (Evusheld) vs. control

COVID 19 all comers

ACTIV-3 (BRII-196 and BRII-198), 2021 NCT04501978

amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences) vs. placebo

COVID 19 hospitalized

ACTIV-3/TICO LY-CoV555 , 2020 NCT04501978

bamlanivimab monotherapy vs. placebo

COVID 19 hospitalized

RECOVERY (REGN-COV2), 2021 NCT04381936

casirivimab/imdevimab (Ronapreve) vs. standard of care

COVID 19 hospitalized

ACTIV-3/TICO (tixa), 2022 NCT04501978

cilgavimab and tixagevimab (Evusheld) vs. placebo

COVID 19 hospitalized

ITAC, 2022 NCT04546581

neutralizing antibody vs. placebo

COVID 19 hospitalized

ACTIV-3/ TICO (sotrovimab), 2021 NCT04501978

sotrovimab (Xevudy; VIR-7831) vs. placebo

COVID 19 hospitalized

phase 2, 0 NCT04787211

amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences) vs. placebo

COVID-19 mild to moderate

CORIMMUNO-BEVA, 0 NCT04344782

bevacizumab vs. standard of care

COVID-19 mild to moderate

Suzuki, 2021

casirivimab/imdevimab (Ronapreve) vs. control

COVID-19 mild to moderate

Somersan-Karakaya (Cohort 1, Cohort 1A; Combined doses), 2021 NCT04426695

casirivimab/imdevimab (Ronapreve) vs. placebo

COVID-19 mild to moderate

POLYCOR phase IIb (Gaborit), 2021 NCT04453384

XAV-19 vs. placebo

COVID-19 mild to moderate

Lopardo, 2021 NCT04494984

equine polyclonal antibodies INM005 vs. placebo

COVID-19 severe or critically